Trial Profile

A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ChAdV68 S (Primary) ; ChAdV68 S TCE (Primary) ; SAM LNP S (Primary) ; SAM LNP S TCE (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Proof of concept
Acronyms CORAL-NIH

19 Oct 2023 Status changed from active, no longer recruiting to completed.
11 Oct 2023 Results published in the Gritstone Oncology Media Release
04 Oct 2023 According to a Gritstone bio media release, data from this study will be presented at the IDWeek 2023, occurring October 11-15, 2023, in Boston, MA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com